Newsfeeds Archive - Page 2 of 7

3 minute read

Nasdaq Gains 50 Points; US Crude Inventories Rise Last Week

January 10, 1:04 PM

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 50 points on Wednesday. The Dow traded up 0.17% to 37,588.15 while the NASDAQ rose 0.34% to 14,908.42. The S&P 500 also rose, gaining, 0.21% to 4,766.64.

ACRS

1 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Pre-Market Session

By Benzinga Insights

January 10, 9:05 AM

Gainers Exicure (NASDAQ:XCUR) stock increased by 29.8% to $0.8 during Wednesday’s pre-market session. The company’s market cap stands…

ACRS

1 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

December 4, 5:31 PM

Gainers Tharimmune (NASDAQ:THAR) stock increased by 19.0% to $0.87 during Monday’s after-market session. The market value of their…

ACRV

6 minute read

Amarin Corp Announces New REDUCE-IT Analyses Show VASCEPA Associated With 29% Relative Risk Reduction Compared With Placebo In Prespecified Subgroup Of Patients With Metabolic Syndrome, But Without Diabetes At Baseline

By Benzinga Newsdesk

November 12, 6:13 PM

-- Analysis Also Found IPE Was Associated with a 41% Reduction in Total Events Compared with Placebo -- -- Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease ---- Findings

AMRN

23 minute read

Earnings

Earnings Scheduled For November 1, 2023

By Benzinga Insights

November 1, 7:19 AM

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.

ABNB

2 minute read

Latest Research Evaluating VASCEPA/VAZKEPA And Subgroups From The REDUCE-IT Landmark Outcomes Trial To Be Presented At The American Heart Association Scientific Sessions 2023

By Benzinga Newsdesk

October 26, 8:16 AM

Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research from the landmark REDUCE-IT cardiovascular outcomes trial on the effects of VASCEPA®/VAZKEPA® (icosapent ethyl) in a

AMRN

2 minute read

Alphabet To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Wednesday

By Lisa Levin

October 25, 8:10 AM

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

AMRN